Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $157000.0.

  • Niagen Bioscience's Depreciation & Amortization (CF) fell 426.83% to $157000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $624000.0, marking a year-over-year decrease of 943.4%. This contributed to the annual value of $663000.0 for FY2024, which is 2379.31% down from last year.
  • Latest data reveals that Niagen Bioscience reported Depreciation & Amortization (CF) of $157000.0 as of Q3 2025, which was down 426.83% from $158000.0 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Depreciation & Amortization (CF) high stood at $235000.0 for Q3 2022, and its period low was $151000.0 during Q4 2024.
  • In the last 5 years, Niagen Bioscience's Depreciation & Amortization (CF) had a median value of $211000.0 in 2021 and averaged $198157.9.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 1343.28% in 2023, then tumbled by 2961.37% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's Depreciation & Amortization (CF) stood at $211000.0 in 2021, then grew by 4.74% to $221000.0 in 2022, then decreased by 19.91% to $177000.0 in 2023, then fell by 14.69% to $151000.0 in 2024, then increased by 3.97% to $157000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $157000.0 for Q3 2025, versus $158000.0 for Q2 2025 and $158000.0 for Q1 2025.